{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T03:56:22Z","timestamp":1791172582001,"version":"4.1.0"},"reference-count":50,"publisher":"American Society of Hematology","issue":"3","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2002,2,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Chronic myelomonocytic leukemia (CMML) is a hematologic malignancy characterized by wide heterogeneity of clinical presentation and course. CMML shares myelodysplastic characteristics with features of myeloproliferative disorders. No treatment has proven effective in modifying the natural course of the disease. To improve the prognostic assessment of clinical outcome, the associations of patient and disease characteristics with survival times of 213 patients with CMML was investigated retrospectively. Median survival was 12 months. Univariate analysis identified low hemoglobin level; low platelet count; high white blood cell, monocyte, and lymphocyte counts; presence of circulating immature myeloid cells, high percentage of marrow blasts, low percentage of marrow erythroid cells, abnormal cytogenetics, and high levels of serum lactate dehydrogenase and \u03b22-microglobulin as characteristics associated with shorter survival. Hemoglobin level below 120 g\/L (12 g\/dL), presence of circulating immature myeloid cells, absolute lymphocyte count above 2.5\u2009\u00d7\u2009109\/L, and marrow blasts 10% or more were independently associated with shorter survival by multivariate analysis and were used to generate a prognostic score. The model identified 4 subgroups of patients with median survival of 24, 15, 8, and 5 months for low, intermediate-1, intermediate-2, and high risk, respectively. Researchers could not confer objective evidence suggesting that arbitrary divisions of CMML by white blood cell counts into \u201cdysplastic\u201d and \u201cproliferative\u201d categories reflect clinical entities differing in the risk of acute leukemia development, although a trend of shorter survival in patients with leukocytosis was observed. The prognostic model was compared with 6 previously published scoring systems for myelodysplastic syndrome\/CMML. The reported results should provide an improved assessment of prognosis in CMML.<\/jats:p>","DOI":"10.1182\/blood.v99.3.840","type":"journal-article","created":{"date-parts":[[2002,7,27]],"date-time":"2002-07-27T12:46:40Z","timestamp":1027774000000},"page":"840-849","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":335,"title":["Prognostic factors and scoring systems in chronic myelomonocytic leukemia: a retrospective analysis of 213 patients"],"prefix":"10.1182","volume":"99","author":[{"given":"Francesco","family":"Onida","sequence":"first","affiliation":[{"name":"From the Department of Leukemia, Department of Biostatistics, and Department of Hematopathology, The University of Texas M. D. Anderson Cancer Center, Houston."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hagop M.","family":"Kantarjian","sequence":"additional","affiliation":[{"name":"From the Department of Leukemia, Department of Biostatistics, and Department of Hematopathology, The University of Texas M. D. Anderson Cancer Center, Houston."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terry L.","family":"Smith","sequence":"additional","affiliation":[{"name":"From the Department of Leukemia, Department of Biostatistics, and Department of Hematopathology, The University of Texas M. D. Anderson Cancer Center, Houston."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Greg","family":"Ball","sequence":"additional","affiliation":[{"name":"From the Department of Leukemia, Department of Biostatistics, and Department of Hematopathology, The University of Texas M. D. Anderson Cancer Center, Houston."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Keating","sequence":"additional","affiliation":[{"name":"From the Department of Leukemia, Department of Biostatistics, and Department of Hematopathology, The University of Texas M. D. Anderson Cancer Center, Houston."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elihu H.","family":"Estey","sequence":"additional","affiliation":[{"name":"From the Department of Leukemia, Department of Biostatistics, and Department of Hematopathology, The University of Texas M. D. Anderson Cancer Center, Houston."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Armand B.","family":"Glassman","sequence":"additional","affiliation":[{"name":"From the Department of Leukemia, Department of Biostatistics, and Department of Hematopathology, The University of Texas M. D. Anderson Cancer Center, Houston."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maher","family":"Albitar","sequence":"additional","affiliation":[{"name":"From the Department of Leukemia, Department of Biostatistics, and Department of Hematopathology, The University of Texas M. D. Anderson Cancer Center, Houston."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica I.","family":"Kwari","sequence":"additional","affiliation":[{"name":"From the Department of Leukemia, Department of Biostatistics, and Department of Hematopathology, The University of Texas M. D. Anderson Cancer Center, Houston."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miloslav","family":"Beran","sequence":"additional","affiliation":[{"name":"From the Department of Leukemia, Department of Biostatistics, and Department of Hematopathology, The University of Texas M. D. Anderson Cancer Center, Houston."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"key":"2020021216141225400_B1","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1016\/S0950-3536(87)80031-8","article-title":"Haematological classification of the chronic myeloid leukaemias.","volume":"1","author":"Shepherd","year":"1987","journal-title":"Baillieres Clin Haematol."},{"key":"2020021216141225400_B2","doi-asserted-by":"crossref","first-page":"343","DOI":"10.3109\/10428199209049789","article-title":"Hematological differences between chronic granulocytic leukemia, atypical chronic myeloid leukemia and chronic myelomonocytic leukemia.","volume":"7","author":"Galton","year":"1992","journal-title":"Leuk Lymphoma."},{"key":"2020021216141225400_B3","doi-asserted-by":"crossref","first-page":"35","DOI":"10.3109\/10428199309148501","article-title":"Chronic myelomonocytic leukaemia (CMML)\u2014a myelodysplastic or myeloproliferative syndrome?","volume":"9","author":"Michaux","year":"1993","journal-title":"Leuk Lymphoma."},{"key":"2020021216141225400_B4","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1111\/j.1365-2141.1994.tb06734.x","article-title":"The chronic myeloid leukaemias: guidelines for distinguishing chronic granulocytic, atypical chronic myeloid, and chronic myelomonocytic leukaemia. Proposals by the French-American-British Cooperative Leukaemia Group.","volume":"87","author":"Bennett","year":"1994","journal-title":"Br J Haematol."},{"key":"2020021216141225400_B5","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/0145-2126(96)00028-8","article-title":"Mixed myelodysplastic and myeloproliferative syndromes.","volume":"20","author":"Neuwirtova","year":"1996","journal-title":"Leuk Res."},{"key":"2020021216141225400_B6","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1159\/000203629","article-title":"A diagnostic dilemma: chronic myelomonocytic leukemia versus atypical chronic myeloid leukemia. A case report and review of the literature.","volume":"98","author":"Misialek","year":"1997","journal-title":"Acta Haematol."},{"key":"2020021216141225400_B7","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/S0268-960X(98)90018-2","article-title":"The myelodysplastic syndromes: towards a functional classification.","volume":"12","author":"Mijovic","year":"1998","journal-title":"Blood Rev."},{"key":"2020021216141225400_B8","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1016\/S0145-2126(98)00063-0","article-title":"The classification of chronic myelomonocytic leukaemia.","volume":"22","author":"Oscier","year":"1998","journal-title":"Leuk Res."},{"key":"2020021216141225400_B9","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1016\/S0145-2126(97)00192-6","article-title":"Problems in the classification of CMML\u2014dysplastic versus proliferative type.","volume":"22","author":"Germing","year":"1998","journal-title":"Leuk Res."},{"key":"2020021216141225400_B10","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1111\/j.1365-2141.1982.tb08475.x","article-title":"Proposals for the classification of the myelodysplastic syndromes.","volume":"51","author":"Bennett","year":"1982","journal-title":"Br J Haematol."},{"key":"2020021216141225400_B11","doi-asserted-by":"crossref","first-page":"3835","DOI":"10.1200\/JCO.1999.17.12.3835","article-title":"World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997.","volume":"17","author":"Harris","year":"1999","journal-title":"J Clin Oncol."},{"key":"2020021216141225400_B12","first-page":"1315","article-title":"Cytogenetic analysis has strong independent prognostic value in de novo myelodysplastic syndromes and can be incorporated in a new scoring system: a report of 408 cases.","volume":"9","author":"Morel","year":"1993","journal-title":"Leukemia."},{"key":"2020021216141225400_B13","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1182\/blood.V63.3.634.634","article-title":"Chronic myelomonocytic leukemia according to FAB classification: analysis of 35 cases.","volume":"63","author":"Solal-Celigny","year":"1984","journal-title":"Blood."},{"key":"2020021216141225400_B14","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1111\/j.1365-2141.1985.tb07329.x","article-title":"Myelodysplastic syndromes: a scoring system with prognostic significance.","volume":"59","author":"Mufti","year":"1985","journal-title":"Br J Haematol."},{"key":"2020021216141225400_B15","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1002\/hon.2900030206","article-title":"Chronic myelomonocytic leukemia: clinical features, cytogenetics, and prognosis in 30 consecutive cases.","volume":"3","author":"Alessandrino","year":"1985","journal-title":"Hematol Oncol."},{"key":"2020021216141225400_B16","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1111\/j.1365-2141.1987.tb06142.x","article-title":"Chronic and subacute myelomonocytic leukemia in the adult: a report of 60 cases with special reference to prognostic factors.","volume":"65","author":"Fenaux","year":"1987","journal-title":"Br J Haematol."},{"key":"2020021216141225400_B17","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1038\/bjc.1987.154","article-title":"Prognostic factors and survival in chronic myelomonocytic leukaemia (CMML).","volume":"56","author":"Stark","year":"1987","journal-title":"Br J Cancer."},{"key":"2020021216141225400_B18","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1111\/j.1600-0609.1988.tb00880.x","article-title":"Myelodysplastic syndromes: analysis of clinical and prognostic features in 96 patients.","volume":"41","author":"van der Weide","year":"1988","journal-title":"Eur J Hematol."},{"key":"2020021216141225400_B19","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1002\/ajh.2830270303","article-title":"Prognostic factors in chronic myelodysplastic syndromes: a multivariate analysis in 107 cases.","volume":"27","author":"Garcia","year":"1988","journal-title":"Am J Hematol."},{"key":"2020021216141225400_B20","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1200\/JCO.1988.6.9.1417","article-title":"Prognostic factors in adult chronic myelomonocytic leukemia: an analysis of 107 cases.","volume":"6","author":"Fenaux","year":"1988","journal-title":"J Clin Oncol."},{"key":"2020021216141225400_B21","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1111\/j.1365-2141.1988.tb04173.x","article-title":"Prognostic features of chronic myelomonocytic leukaemia: a modified Bournemouth score gives the best prediction of survival.","volume":"68","author":"Worsley","year":"1988","journal-title":"Br J Haematol."},{"issue":"1","key":"2020021216141225400_B22","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1182\/blood.V74.1.395.395","article-title":"Two regression models and a scoring system for predicting survival and planning treatment in myelodysplastic syndromes: a multivariate analysis of prognostic factors in 370 patients.","volume":"74","author":"Sanz","year":"1989","journal-title":"Blood."},{"key":"2020021216141225400_B23","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1111\/j.1600-0609.1989.tb01472.x","article-title":"Chronic myelomonocytic leukemia\u2014clinicobiological characteristics: a multivariate analysis in a series of 70 cases.","volume":"42","author":"del Canizo","year":"1989","journal-title":"Eur J Haematol."},{"key":"2020021216141225400_B24","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1016\/S0025-6196(12)61287-7","article-title":"Chronic myelomonocytic leukemia: natural history and prognostic determinants.","volume":"64","author":"Tefferi","year":"1989","journal-title":"Mayo Clin Proc."},{"key":"2020021216141225400_B25","first-page":"766","article-title":"Chronic myelomonocytic leukemia.","volume":"4","author":"Storniolo","year":"1990","journal-title":"Leukemia."},{"key":"2020021216141225400_B26","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/0145-2126(90)90133-T","article-title":"Prognostic factors of myelodysplastic syndromes: a simplified 3-D scoring system.","volume":"14","author":"Goasguen","year":"1990","journal-title":"Leuk Res."},{"key":"2020021216141225400_B27","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/0165-4608(91)90235-M","article-title":"Chronic myelomonocytic leukemia: single entity or heterogeneous disorder? A prospective multicenter study of 100 patients. Groupe Francais de Cytogenetique Hematologique.","volume":"55","year":"1991","journal-title":"Cancer Genet Cytogenet."},{"key":"2020021216141225400_B28","first-page":"52","article-title":"Primary myelodysplastic syndromes: analysis of prognostic factors in 235 patients and proposals for an improved scoring system.","volume":"6","author":"Aul","year":"1992","journal-title":"Leukemia."},{"key":"2020021216141225400_B29","first-page":"499","article-title":"Clinical implications of chromosomal abnormalities in 401 patients with myelodysplastic syndromes: a multicentric study in Japan.","volume":"7","author":"Toyama","year":"1993","journal-title":"Leukemia."},{"key":"2020021216141225400_B30","first-page":"324","article-title":"Prognosis of chronic myelomonocytic leukemia.","volume":"81","author":"Catalano","year":"1996","journal-title":"Haematologica."},{"key":"2020021216141225400_B31","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/S0889-8588(18)30494-5","article-title":"Philadelphia chromosome-negative chronic myelogenous leukemia and chronic myelomonocytic leukemia.","volume":"4","author":"Kantarjian","year":"1990","journal-title":"Hematol Oncol Clin North Am."},{"key":"2020021216141225400_B32","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1182\/blood.V75.2.445.445","article-title":"Philadelphia chromosome-negative chronic myelogenous leukemia without breakpoint cluster region rearrangement: a chronic myeloid leukemia with a distinct clinical course.","volume":"75","author":"Kurzrock","year":"1990","journal-title":"Blood."},{"key":"2020021216141225400_B33","first-page":"61","volume-title":"Statistical Design and Analysis of Experiments.","author":"Mason","year":"1989"},{"key":"2020021216141225400_B34","first-page":"59","volume-title":"Classification and Regression Trees.","author":"Breiman","year":"1984"},{"key":"2020021216141225400_B35","first-page":"10","volume-title":"CART: Tree-Structured Non-Parametric Data Analysis.","author":"Steinberg","year":"1995"},{"key":"2020021216141225400_B36","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/j.2517-6161.1972.tb00899.x","article-title":"Regression models and life tables [with discussion].","volume":"34","author":"Cox","year":"1972","journal-title":"J Stat Soc."},{"key":"2020021216141225400_B37","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1093\/biomet\/77.1.147","article-title":"Martingale-based residuals for survival models.","volume":"77","author":"Therneau","year":"1990","journal-title":"Biometrika."},{"key":"2020021216141225400_B38","first-page":"70","volume-title":"The Statistical Analysis of Failure Time Data.","author":"Kalbfleisch","year":"1980"},{"key":"2020021216141225400_B39","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1182\/blood.V89.6.2079","article-title":"International scoring system for evaluating prognosis in myelodysplastic syndromes.","volume":"89","author":"Greenberg","year":"1997","journal-title":"Blood."},{"key":"2020021216141225400_B40","first-page":"258","article-title":"Diagnosis, classification, and cytogenetics of myelodysplastic syndromes.","volume":"83","author":"Vallespi","year":"1998","journal-title":"Haematologica."},{"key":"2020021216141225400_B41","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1111\/j.1365-2141.1987.tb06858.x","article-title":"A multivariate analysis of prognostic factors in chronic myelomonocytic leukaemia according to the FAB criteria.","volume":"65","author":"Ribera","year":"1987","journal-title":"Br J Haematol."},{"key":"2020021216141225400_B42","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/0165-4608(86)90197-4","article-title":"Cytogenetics of chronic myelomonocytic leukemia.","volume":"21","year":"1986","journal-title":"Cancer Genet Cytogenet."},{"key":"2020021216141225400_B43","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1182\/blood.V75.4.823.823","article-title":"Prognostic value of pretreatment serum \u03b2 2-microglobulin in myeloma: a Southwest Oncology Group Study.","volume":"75","author":"Durie","year":"1990","journal-title":"Blood."},{"key":"2020021216141225400_B44","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1200\/JCO.1989.7.10.1518","article-title":"A new serologic staging system for large cell lymphomas based on initial \u03b2 2-microglobulin and lactate dehydrogenase levels.","volume":"7","author":"Swan","year":"1989","journal-title":"J Clin Oncol."},{"key":"2020021216141225400_B45","first-page":"107","article-title":"Chronic lymphocytic leukemia.","volume":"26","author":"Keating","year":"1999","journal-title":"Semin Oncol."},{"key":"2020021216141225400_B46","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/0092-8674(94)90322-0","article-title":"Fusion of PDGF receptor \u03b2 to a novel ets-like gene, tel, in chronic myelomonocytic leukemia with t(5;12) chromosomal translocation.","volume":"77","author":"Golub","year":"1994","journal-title":"Cell."},{"key":"2020021216141225400_B47","doi-asserted-by":"crossref","first-page":"2535","DOI":"10.1182\/blood.V90.7.2535","article-title":"Fusion of TEL, the ETS-variant gene 6 (ETV6), to the receptor-associated kinase JAK2 as a result of t(9;12) in a lymphoid and t(9;15;12) in a myeloid leukemia.","volume":"90","author":"Peeters","year":"1997","journal-title":"Blood."},{"key":"2020021216141225400_B48","doi-asserted-by":"crossref","first-page":"4419","DOI":"10.1182\/blood.V91.12.4419","article-title":"Fusion of Huntingtin interacting protein 1 to platelet-derived growth factor \u03b2 receptor (PDGF\u03b2R) in chronic myelomonocytic leukemia with t(5;7)(q33;q11.2).","volume":"91","author":"Ross","year":"1998","journal-title":"Blood."},{"key":"2020021216141225400_B49","doi-asserted-by":"crossref","first-page":"5321","DOI":"10.1093\/emboj\/17.18.5321","article-title":"Transformation of hematopoietic cell lines to growth factor independence and induction of a fatal myelo- and lymphoproliferative disease in mice by retrovirally transduced TEL\/JAK2 fusion genes.","volume":"17","author":"Schwaller","year":"1998","journal-title":"EMBO J."},{"key":"2020021216141225400_B50","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1182\/blood.V97.5.1435","article-title":"Induction of myeloproliferative disease in mice by tyrosine kinase fusion oncogenes does not require granulocyte-macrophage colony-stimulating factor or interleukin-3.","volume":"97","author":"Tomasson","year":"2001","journal-title":"Blood."}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/99\/3\/840\/1680289\/840.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/99\/3\/840\/1680289\/840.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,9]],"date-time":"2024-12-09T00:11:04Z","timestamp":1733703064000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/99\/3\/840\/53495\/Prognostic-factors-and-scoring-systems-in-chronic"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,2,1]]},"references-count":50,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2002,2,1]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.v99.3.840","relation":{},"ISSN":["1528-0020","0006-4971"],"issn-type":[{"value":"1528-0020","type":"electronic"},{"value":"0006-4971","type":"print"}],"subject":[],"published":{"date-parts":[[2002,2,1]]}}}